Fig. 4

Drug sensitivity analysis and identifying related pathways. a Identification of drug sensitivity between high-risk group and low-risk group. b Correlation of drug targets and risk score in TCGA-KIRC cohort. c Pearson’s correlation analysis of functional pathways and risk score in TCGA-KIRC cohort. d Correlations between risk score and immune checkpoints. e Comparison of the enrichment of functional pathways by GSEA analysis of different related risk score. f KEGG enrichment of DEGs. g GO enrichment analysis of the top 30 pathways in different risk groups. h The ROC curve of joint indicators and multi-model comparison in TCGA-KIRC cohort